{"id":9284,"date":"2021-04-19T10:00:47","date_gmt":"2021-04-19T17:00:47","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9284"},"modified":"2021-04-20T10:01:24","modified_gmt":"2021-04-20T17:01:24","slug":"efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-chronic-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/19\/efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-chronic-lymphocytic-leukemia\/","title":{"rendered":"Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among patients with chronic lymphocytic leukemia (CLL, n = 169) who received two doses of the Pfizer-BioNTech vaccine, the antibody response rate was 39.5% as measured by the <\/span><span style=\"font-weight: 400\">Elecsys Anti-SARS-CoV-2 assay at a median of 15 days after the second dose. Compared to age- and sex-matched controls, the response rate among patients with CLL was significantly reduced <\/span><span style=\"font-weight: 400\">(aOR <\/span><span style=\"font-weight: 400\">=0.01). The response rate was highest in patients who were in remission after treatment (79.2%), followed by 55.2% in treatment-na\u00efve and 16% in patients undergoing treatment at the time of vaccination. In patients treated with either Bruton tyrosine kinase inhibitors or venetoclax with or without anti-CD20 antibody, response rates were low (16.0% and 13.6%, respectively).\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Herishanu et al.\u00a0(Apr 2021). Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1182\/blood.2021011568\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1182\/blood.2021011568<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among patients with chronic lymphocytic leukemia (CLL, n = 169) who received two doses of the Pfizer-BioNTech vaccine, the antibody response rate was 39.5% as measured by the Elecsys Anti-SARS-CoV-2 assay at a median of 15 days after the second dose. Compared to age- and sex-matched controls, the response rate among patients with CLL was&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/19\/efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-chronic-lymphocytic-leukemia\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142],"topic":[31],"class_list":["post-9284","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9284"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9284\/revisions"}],"predecessor-version":[{"id":9285,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9284\/revisions\/9285"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9284"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}